Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 10, 2026
Dianthus Therapeutics, Inc. /De/ (DNTH)
A forensic read on Dianthus Therapeutics, Inc. /De/ built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Grey Zone
Financial health
13.0
Distress distance
Clean
Earnings quality
3
Forensic signals
-828.5
P / E (ttm)
-32.9%
ROE
$6.1B
Market cap
0.00%
Dividend yield
-67.3%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Dianthus Therapeutics, Inc. /De/ earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads 13.0, placing it in the Grey zone. 3 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).
What the filings flag
+29.2%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +29.2% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building sharply — a large slice of profit sits in operating assets, not cash; Richardson/Sloan link high accruals to weaker future returns as they reverse. The build is led by PP&E up +53% against revenue -67%. The cash-flow cross-check is more mixed: reported earnings ran behind operating cash by 9% of net operating assets, diverging from the balance-sheet accrual read.
n/m (stock split)
FY2022–FY2025
Share count (stock split).Diluted share count changed +4317% over the last 3 years to FY2025, but that includes a large one-time change around FY2023 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw +253.5%/yr figure isn't a real buyback/dilution read here.
1119% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 1119% of revenue in FY2025 — about $0.59 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count, and there it has run at about 20.5% a year and is falling.
Key fundamentals
Latest Revenue$2.0M
Revenue Growth YoY-67.3%
Net Margin-7973.3%
Free Cash Flow-$129.3M
Return on Equity-32.9%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Dianthus Therapeutics, Inc. /De/'s actual 10-K/10-Q/8-K filings?